×
About 750 results

ALLMedicine™ Urinary Free Cortisol Center

Research & Reviews  245 results

Effect of external sleep disturbance on sleep architecture in perimenopausal and postme...
https://doi.org/10.1080/13697137.2022.2158727
Climacteric : the Journal of the International Menopause ... Virtanen I, Polo-Kantola P et. al.

Jan 23rd, 2023 - This study aimed to use external sleep disturbance as a model to evaluate sleep architecture in climacteric women before and after menopausal hormone therapy (MHT). Seventeen perimenopausal and 18 postmenopausal women underwent a polysomnography p...

Clinical characteristics of patients with unexplainable hypothalamic disorder diagnosed...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733005
BMC Endocrine Disorders; Hataya Y, Okubo M et. al.

Dec 11th, 2022 - The corticotropin-releasing hormone (CRH) challenge test can distinguish the disorders of the hypothalamus from those of the pituitary. However, the pathophysiology of hypothalamic disorder (HD) has not been fully understood. This study aimed to e...

Efficacy and safety of osilodrostat in paraneoplastic Cushing's syndrome: a real-world ...
https://doi.org/10.1210/clinem/dgac691
The Journal of Clinical Endocrinology and Metabolism; Dormoy A, Haissaguerre M et. al.

Dec 6th, 2022 - Prospective studies have demonstrated the efficacy of osilodrostat in Cushing's disease. No study has evaluated osilodrostat in a series of patients with paraneoplastic Cushing's syndrome/ectopic ACTH syndrome (PNCS/EAS). Evaluate in France the re...

SAlt Diet and Various Biomarkers Effects on Blood Pressure and Proteinuria During Inhibition of VEGF)
https://clinicaltrials.gov/ct2/show/NCT03842917

Nov 8th, 2022 - Participants will be invited to participate to this research study by their oncologist within 1 to 2 weeks before starting bevacizumab treatment, as part of standard treatment. They will finish the research at the end of the third infusion of beva...

Hypothalamic-pituitary-adrenal axis activity in patients with primary polydipsia compar...
https://doi.org/10.1111/cen.14835
Clinical Endocrinology; Sailer CO, Kuehne JM et. al.

Oct 21st, 2022 - Primary polydipsia is characterized by excessive fluid intake which may suppress vasopressin levels. It is speculated that suppressed vasopressin levels lead to a dysregulated hypothalamic-pituitary-adrenal (HPA) axis as vasopressin co-modulates t...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  14 results

SAlt Diet and Various Biomarkers Effects on Blood Pressure and Proteinuria During Inhibition of VEGF)
https://clinicaltrials.gov/ct2/show/NCT03842917

Nov 8th, 2022 - Participants will be invited to participate to this research study by their oncologist within 1 to 2 weeks before starting bevacizumab treatment, as part of standard treatment. They will finish the research at the end of the third infusion of beva...

Treatment of Cushing's Disease With R-roscovitine
https://clinicaltrials.gov/ct2/show/NCT02160730

Nov 4th, 2021 - To date, R-roscovitine (seliciclib) has been evaluated in several Phase I and II studies and has shown early signs of anti-cancer activity in approximately 240 patients. Studies included a Phase I study in which single agent seliciclib was adminis...

Growth Hormone Pretreatment in Poseidon Type IV Undergoing ICSI Using Minimal Induction Protocol: A Randomized Controlled Trial
https://clinicaltrials.gov/ct2/show/NCT05089344

Oct 22nd, 2021 - Patients are recruited from the attendee of the Infertility clinic and IVF unit in maternity hospital Ain shams university who are eligible for the trial. Procedure will be done by Prof . Dr Mostafa Fouad . and Lecturer Dr Ebtihal ElTaieb * Proper...

Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms
https://clinicaltrials.gov/ct2/show/NCT03974789

Oct 5th, 2021 - Automated immunodosage methods (Roche Elecsys cortisol and IDS cortisol dosing kits) offer a simple and inexpensive technology routinely used in a medical biology laboratory. They can be used to define robust diagnostic thresholds for salivary cor...

Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome
https://clinicaltrials.gov/ct2/show/NCT02297945

Sep 25th, 2020 - This study will include Cushing disease patients with persistent or recurrent disease (after pituitary surgery) or who are newly diagnosed but are unsuitable for early surgery or wish to defer surgery. It will also include patients with ectopic AC...

see more →

News  35 results

FDA OKs Endogenous Cushing's Syndrome Treatment
https://www.medpagetoday.com/endocrinology/steroids/96481

Jan 4th, 2022 - The FDA approved a new treatment for adults with endogenous hypercortisolemia related to Cushing's syndrome, Xeris Biopharma announced late last week. The oral drug levoketoconazole (Recorlev) is indicated for the treatment of endogenous hypercort...

Heavy Periods Seen in Obesity; T1D Tied to Fracture Risk
https://www.medpagetoday.com/endocrinology/generalendocrinology/92027

Apr 11th, 2021 - Women with obesity may have a higher risk of heavier periods due to delayed endometrial repair. "Although it is difficult to make strong recommendations based on this study alone, a common-sense approach would be to offer weight-loss support to wo...

Metyrapone for Cushing’s syndrome: Safe, effective in first test
https://www.mdedge.com/endocrinology/article/237622/hypercortisolism/metyrapone-cushings-syndrome-safe-effective-first-test
Mitchel L. Zoler, PhD

Mar 24th, 2021 - Metyrapone, an inhibitor of endogenous adrenal corticosteroid synthesis currently used in U. S.

FDA OKs Octreotide Capsules; COVID-19 Damages Endocrine System
https://www.medpagetoday.com/endocrinology/generalendocrinology/87394

Jul 3rd, 2020 - The FDA approved octreotide (Mycapssa) capsules for long-term maintenance of acromegaly in those already treated with octreotide or lanreotide, Chiasma announced. Certain medication and medical devices may inadvertently expose patients to harmful ...

New Drug Alternative for Cushing's Syndrome?
https://www.medpagetoday.com/endocrinology/generalendocrinology/82567

Oct 4th, 2019 - New phase III clinical trial data suggests that an investigational oral drug, levoketoconazole, might be a useful therapeutic option for patients with Cushing syndrome, the study's authors said. The open-label, non-randomized trial included 94 pat...

see more →